Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity

被引：39

作者：

Clynes, Raphael

机构：

[1] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA

[2] Columbia Univ, Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2006年 / 20卷 / 03期

关键词：

D O I：

10.1016/j.hoc.2006.02.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Engineered antibody therapeutics have provided new treatment options in cancer. Genetic evidence in man and in the mouse suggests that Fc receptor (FcR) engagement contributes mechanistically to the therapeutic activity of naked antibodies. Preferential activation of activating FcRs and limited engagement of inhibitory FcRs enhance tumor responses in mouse models. Thus, engineered Fc domains with favorable affinities for specific FcR types may prove to be clinically superior. © 2006 Elsevier Inc. All rights reserved.

引用

收藏

页码：585 / 612

页数：28

相关论文

共 134 条

[81] Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma [J].

Niwa, R ;

Shoji-Hosaka, E ;

Sakurada, M ;

Shinkawa, T ;

Uchida, K ;

Nakamura, K ;

Matsushima, K ;

Ueda, R ;

Hanai, N ;

Shitara, K .

CANCER RESEARCH, 2004, 64 (06) :2127-2133

[82] Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa [J].

Okazaki, A ;

Shoji-Hosaka, E ;

Nakamura, K ;

Wakitani, M ;

Uchida, K ;

Kakita, S ;

Tsumoto, K ;

Kumagai, I ;

Shitara, K .

JOURNAL OF MOLECULAR BIOLOGY, 2004, 336 (05) :1239-1249

[83] Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors [J].

Otten, MA ;

Rudolph, E ;

Dechant, M ;

Tuk, CW ;

Reijmers, RM ;

Beelen, RHJ ;

van de Winkel, JGJ ;

van Egmond, M .

JOURNAL OF IMMUNOLOGY, 2005, 174 (09) :5472-5480

[84] Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor:: Intervention of FcγRII(CD32), CD11b-CD18 integrins, and CD66b glycoproteins [J].

Ottonello, L ;

Epstein, AL ;

Dapino, P ;

Barbara, P ;

Morone, P ;

Dallegri, F .

BLOOD, 1999, 93 (10) :3505-3511

[85] Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients:: stimulation by GM-CSF and role of Fcγ-receptors [J].

Ottonello, L ;

Epstein, AL ;

Mancini, M ;

Tortolina, G ;

Dapino, P ;

Dallegri, F .

BRITISH JOURNAL OF CANCER, 2001, 85 (03) :463-469

[86] Engineering therapeutic antibodies for improved function [J].

Presta, LG ;

Shields, RL ;

Namenuk, AK ;

Hong, K ;

Meng, YG .

BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 :487-490

[87] Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines [J].

Pricop, L ;

Redecha, P ;

Teillaud, JL ;

Frey, J ;

Fridman, WH ;

Sautès-Fridman, C ;

Salmon, JE .

JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :531-537

[88] Impaired mast cell-dependent natural immunity in complement C3-deficient mice [J].

Prodeus, AP ;

Zhou, XN ;

Maurer, M ;

Galli, SJ ;

Carroll, MC .

NATURE, 1997, 390 (6656) :172-175

[89] Recognition of IgG by Fcγ receptor -: The role of Fc glycosylation and the binding of peptide inhibitors [J].

Radaev, S ;

Sun, PD .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16478-16483

[90] Immune complex-mediated antigen presentation induces tumor immunity [J].

Rafiq, K ;

Bergtold, A ;

Clynes, R .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (01) :71-79

← 4 5 6 7 8 9 10 11 12 13 →